About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
ASCO & ESMO Lung Recap: 2L Lurbinectedin in SCLC - Phase 3 Atlantis Trial
By
GRACE
FEATURING
Jack West
,
Isabel Preeshagul
,
Joan Schiller
By
GRACE
FEATURING
Jack West
,
Isabel Preeshagul
,
Joan Schiller
76 views
February 9, 2022
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
25:18
Janakiraman Subramanian
Updates in Small Cell Lung Carcinoma
18:35
2023 Evolution Conference
Recent Updates in SCLC
Feat.
S. Kazmi
10:49
Niels Reinmuth
CASPIAN Trial: Clinical Implications of a 3-Year OS Update of Durval…
17:09
Stanford Medicine
New Drugs for Small Cell Lung Cancer
Feat.
M. Das
07:17
Misty Shields
The Importance of Staying on Therapy for SCLC to Achieve Optimal Ben…
22:11
Insights from ELCC 2024
ELCC 2024 Insights: "Recent Advances and Challenges - Non-IO Ap…
Feat.
M. Früh
04:18
Integrity Continuing Education
Advancing Care for Patients With SCLC
Feat.
N. Florez,
E. Rodriguez,
C. Smith
10:16
Jerome Goldschmidt
National Platinum Chemo Shortages: Impact on Lung Cancer Treatment a…
08:53
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "CASPIAN Study Phase 3 Updates: The Progno…
Feat.
A. Ganti
14:25
Alejandro Navarro
Dissecting SKYSCRAPER-02 Trial - TIGIT Story: From Hope to Nihilism
28:49
European School of Oncology
Management of SCLC: Guidelines ESMO & NCCN
Feat.
A. Passaro
05:13
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Phase 3 LAGOON Study - Lurbinectedin Al…
Feat.
B. Besse
12:25
Lowell Hart
Burden of Chemo-Induced Myelosuppression Among Patients With ES-SCLC…
18:08
OncoAlert
Recent Advances in SCLC
Feat.
J. Naidoo
19:22
Northwell Health
Current Treatment Landscape in SCLC
Feat.
N. Seetharamu
22:38
Ivo Abraham
Trilaciclib and the Economic Value of Multilineage Myeloprotection F…
04:05
ASCO 2022 Conference Coverage
ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolim…
Feat.
J. Sands
16:40
Total Health
Emerging Approaches to Small Cell Lung Cancer
Feat.
J. Rotow
06:08
GRACE
ASCO® 2023 Insights: "Emerging Treatment Options for Patients W…
Feat.
J. West,
C. Lovly,
A. Addeo
20:17
PrecisCa
Expert Panel Case Discussion: 65 y/o Male With Stage 3B SCLC
Feat.
X. von Buttlar,
R. Mudad,
W. Curran,
E. Santos,
T. Stinchcombe,
J. West
